Harmony Biosciences Holdings Inc
HRMY38.130USD
-0.360-0.94%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
2.20BMarket Cap
11.81P/E TTM
More Details of Harmony Biosciences Holdings Inc Company
Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Harmony Biosciences Holdings Inc Info
Ticker SymbolHRMY
Company nameHarmony Biosciences Holdings Inc
IPO dateAug 19, 2020
CEODayno (Jeffrey M)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endAug 19
Address630 W Germantown Pike
CityPLYMOUTH MEETING
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19462
Phone14845399800
Websitehttps://www.harmonybiosciences.com/
Ticker SymbolHRMY
IPO dateAug 19, 2020
CEODayno (Jeffrey M)
Company Executives of Harmony Biosciences Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Antonio Gracias
Mr. Antonio Gracias
Independent Director
Independent Director
533.63K
+1353.47%
Mr. Jeffrey S. (Jeff) Aronin
Mr. Jeffrey S. (Jeff) Aronin
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
251.92K
--
Dr. Kumar Budur, M.D.
Dr. Kumar Budur, M.D.
Executive Vice President and Chief Medical and Scientific Officer
Executive Vice President and Chief Medical and Scientific Officer
10.89K
+983.18%
Mr. Andrew Serafin, J.D.
Mr. Andrew Serafin, J.D.
Chief Strategy Officer
Chief Strategy Officer
1.64K
--
Mr. Adam Zaeske
Mr. Adam Zaeske
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Ron Philip
Mr. Ron Philip
Independent Director
Independent Director
--
--
Dr. Andreas Wicki, Ph.D.
Dr. Andreas Wicki, Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Mark Graf
Mr. R. Mark Graf
Independent Director
Independent Director
--
--
Mr. Gary L. Sender
Mr. Gary L. Sender
Independent Director
Independent Director
--
--
Dr. Jeffrey M. (Jeff) Dayno, M.D.
Dr. Jeffrey M. (Jeff) Dayno, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Antonio Gracias
Mr. Antonio Gracias
Independent Director
Independent Director
533.63K
+1353.47%
Mr. Jeffrey S. (Jeff) Aronin
Mr. Jeffrey S. (Jeff) Aronin
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
251.92K
--
Dr. Kumar Budur, M.D.
Dr. Kumar Budur, M.D.
Executive Vice President and Chief Medical and Scientific Officer
Executive Vice President and Chief Medical and Scientific Officer
10.89K
+983.18%
Mr. Andrew Serafin, J.D.
Mr. Andrew Serafin, J.D.
Chief Strategy Officer
Chief Strategy Officer
1.64K
--
Mr. Adam Zaeske
Mr. Adam Zaeske
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Ron Philip
Mr. Ron Philip
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2022
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
200.49M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Marshman Fund Trust ii
10.51%
BlackRock Institutional Trust Company, N.A.
10.15%
The Vanguard Group, Inc.
8.83%
Fidelity Management & Research Company LLC
6.68%
HBM Partners AG
3.73%
Other
60.11%
Shareholders
Shareholders
Proportion
Marshman Fund Trust ii
10.51%
BlackRock Institutional Trust Company, N.A.
10.15%
The Vanguard Group, Inc.
8.83%
Fidelity Management & Research Company LLC
6.68%
HBM Partners AG
3.73%
Other
60.11%
Shareholder Types
Shareholders
Proportion
Investment Advisor
48.54%
Investment Advisor/Hedge Fund
24.05%
Corporation
10.51%
Hedge Fund
6.00%
Research Firm
4.41%
Private Equity
3.05%
Individual Investor
1.63%
Pension Fund
1.23%
Bank and Trust
0.48%
Other
0.10%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
556
48.04M
83.41%
-15.75M
2025Q2
552
60.78M
105.69%
-11.17M
2025Q1
573
60.17M
104.79%
-12.54M
2024Q4
571
62.71M
109.35%
-5.92M
2024Q3
559
64.22M
112.66%
-9.33M
2024Q2
548
64.68M
113.76%
-9.02M
2024Q1
546
63.23M
110.16%
-590.81K
2023Q4
534
62.18M
105.68%
-302.40K
2023Q3
502
63.52M
115.31%
-874.73K
2023Q2
488
66.12M
110.24%
+3.64M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Marshman Fund Trust ii
6.05M
10.52%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.77M
10.03%
+154.94K
+2.76%
Jun 30, 2025
The Vanguard Group, Inc.
5.10M
8.87%
+412.76K
+8.80%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.69M
8.15%
-654.33K
-12.25%
Jun 30, 2025
HBM Partners AG
2.15M
3.73%
--
--
Mar 17, 2025
Dimensional Fund Advisors, L.P.
1.58M
2.75%
+357.38K
+29.18%
Jun 30, 2025
American Century Investment Management, Inc.
1.50M
2.61%
+212.63K
+16.50%
Jun 30, 2025
State Street Investment Management (US)
1.63M
2.83%
+50.21K
+3.18%
Jun 30, 2025
LSV Asset Management
1.49M
2.59%
+293.54K
+24.56%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
906.91K
1.58%
+508.50K
+127.63%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
2.24%
Invesco Pharmaceuticals ETF
2.05%
Virtus LifeSci Biotech Products ETF
1.37%
Euclidean Fundamental Value ETF
1.18%
First Trust Small Cap US Equity Select ETF
1.14%
VictoryShares Small Cap Free Cash Flow ETF
0.96%
ETC 6 Meridian Small Cap Equity ETF
0.93%
Invesco S&P SmallCap 600 Pure Growth ETF
0.8%
Invesco S&P SmallCap Health Care ETF
0.69%
First Trust Small Cap Value AlphaDEX Fund
0.54%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.24%
Invesco Pharmaceuticals ETF
Proportion2.05%
Virtus LifeSci Biotech Products ETF
Proportion1.37%
Euclidean Fundamental Value ETF
Proportion1.18%
First Trust Small Cap US Equity Select ETF
Proportion1.14%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.96%
ETC 6 Meridian Small Cap Equity ETF
Proportion0.93%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion0.8%
Invesco S&P SmallCap Health Care ETF
Proportion0.69%
First Trust Small Cap Value AlphaDEX Fund
Proportion0.54%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Harmony Biosciences Holdings Inc?
The top five shareholders of Harmony Biosciences Holdings Inc are:
Marshman Fund Trust ii holds 6.05M shares, accounting for 10.52% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.77M shares, accounting for 10.03% of the total shares.
The Vanguard Group, Inc. holds 5.10M shares, accounting for 8.87% of the total shares.
Fidelity Management & Research Company LLC holds 4.69M shares, accounting for 8.15% of the total shares.
HBM Partners AG holds 2.15M shares, accounting for 3.73% of the total shares.
Marshman Fund Trust ii holds 6.05M shares, accounting for 10.52% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.77M shares, accounting for 10.03% of the total shares.
The Vanguard Group, Inc. holds 5.10M shares, accounting for 8.87% of the total shares.
Fidelity Management & Research Company LLC holds 4.69M shares, accounting for 8.15% of the total shares.
HBM Partners AG holds 2.15M shares, accounting for 3.73% of the total shares.
What are the top three shareholder types of Harmony Biosciences Holdings Inc?
The top three shareholder types of Harmony Biosciences Holdings Inc are:
Marshman Fund Trust ii
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Marshman Fund Trust ii
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
How many institutions hold shares of Harmony Biosciences Holdings Inc (HRMY)?
As of 2025Q3, 556 institutions hold shares of Harmony Biosciences Holdings Inc, with a combined market value of approximately 48.04M, accounting for 83.41% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -22.28%.
What is the biggest source of revenue for Harmony Biosciences Holdings Inc?
In FY2025Q2, the -- business generated the highest revenue for Harmony Biosciences Holdings Inc, amounting to -- and accounting for --% of total revenue.
